Literature DB >> 16787912

The exercise of public health powers in cases of infectious disease: human rights implications. Enhorn v. Sweden.

Robyn Martin1.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 16787912     DOI: 10.1093/medlaw/fwi038

Source DB:  PubMed          Journal:  Med Law Rev        ISSN: 0967-0742            Impact factor:   1.267


× No keyword cloud information.
  8 in total

1.  International public health law: not so much WHO as why, and not enough WHO and why not?

Authors:  Shawn H E Harmon
Journal:  Med Health Care Philos       Date:  2009-01-10

2.  Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy.

Authors:  M C Payen; J P VAN Vooren; O Vandenberg; N Clumeck; S DE Wit
Journal:  Epidemiol Infect       Date:  2017-02-16       Impact factor: 4.434

3.  XDR-TB in South Africa: no time for denial or complacency.

Authors:  Jerome Amir Singh; Ross Upshur; Nesri Padayatchi
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

4.  Sinophobia during the Covid-19 Pandemic: Identity, Belonging, and International Politics.

Authors:  Zhipeng Gao
Journal:  Integr Psychol Behav Sci       Date:  2021-10-04       Impact factor: 1.156

5.  Compulsory vaccination against COVID-19: a legal and ethical perspective on public good versus personal reticence.

Authors:  Colum P Dunne; Eimear Spain
Journal:  Ir J Med Sci       Date:  2022-02-25       Impact factor: 1.568

6.  Voluntary vaccination: the pandemic effect.

Authors:  Emma Cave
Journal:  Leg Stud (Soc Leg Scholars)       Date:  2016-12-01

7.  The power of detention in the management of non-compliance with tuberculosis treatment: a survey of Irish practitioners and analysis of potential legal liability.

Authors:  S T Duffy
Journal:  Public Health       Date:  2008-12-16       Impact factor: 2.427

8.  The role of law in pandemic influenza preparedness in Europe.

Authors:  R Martin
Journal:  Public Health       Date:  2009-03-04       Impact factor: 2.427

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.